ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2026
Artificial intelligence empowered biomaterials for cancer therapy: From rational design to clinical translation.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor biomaterials show great potential for targeted cancer therapy, yet their development and clinical translation have long been hampered by inefficient empirical trial-and-error models. These traditional methods cannot fully characterize the nonlinear relationships between a material's physicochemical properties and its complex biological effects, nor can they resolve tumor heterogeneity-the primary cause of inconsistent clinical outcomes. This review systematically explores the application of artificial intelligence (AI) across the entire development pipeline of tumor biomaterials, from early rational material design to clinical treatment optimization. We show that AI addresses key bottlenecks in the field in four core ways: it speeds up novel material discovery via generative algorithms, accurately predicts the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.